Due to this dual effect and its capability to cross the blood-brain barrier, ORY-2001 entered in 2019 the phase IIa clinical trial for the treatment of mild to moderate Alzheimer’s diseases (Mehndiratta and Liou, 2020), it being the only LSD1 inhibitor with an indication for treatment of neurogenerative diseases. Here, KDM1A is linked to early-onset autosomal dominant Alzheimer disease.